Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Cassava Sciences (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, has announced it will hold a conference call and webcast on Thursday, November 7th, 2024, at 8:30 a.m. Eastern Time to report its third quarter 2024 results. The audio webcast will be accessible through the company's website and will remain available for replay for 90 days following the event.
Cassava Sciences (Nasdaq: SAVA), un'azienda biotecnologica in fase clinica focalizzata sulla malattia di Alzheimer, ha annunciato che terrà una conferenza telefonica e un webcast il giovedì 7 novembre 2024, alle 8:30 a.m. ora orientale per riportare i risultati del terzo trimestre 2024. Il webcast audio sarà accessibile tramite il sito web dell'azienda e rimarrà disponibile per la riproduzione per 90 giorni dopo l'evento.
Cassava Sciences (Nasdaq: SAVA), una empresa biotecnológica en fase clínica centrada en la enfermedad de Alzheimer, ha anunciado que llevará a cabo una llamada de conferencia y un webcast el jueves 7 de noviembre de 2024, a las 8:30 a.m. hora del Este para informar sobre sus resultados del tercer trimestre de 2024. El webcast de audio será accesible a través del sitio web de la empresa y estará disponible para repetición durante 90 días después del evento.
카사바 사이언스(Cassava Sciences, Nasdaq: SAVA)는 알츠하이머 병에 집중하는 임상 단계의 생명공학 회사로, 2024년 11월 7일 목요일, 동부 표준시 기준으로 오전 8시 30분에 2024년 3분기 실적을 보고하기 위한 컨퍼런스 콜 및 웹캐스트를 개최한다고 발표했습니다. 오디오 웹캐스트는 회사 웹사이트를 통해 접근할 수 있으며 이벤트 이후 90일 동안 다시 들을 수 있습니다.
Cassava Sciences (Nasdaq: SAVA), une entreprise de biotechnologie en phase clinique axée sur la maladie d'Alzheimer, a annoncé qu'elle tiendra une conférence téléphonique et un webcast le jeudi 7 novembre 2024, à 8h30, heure de l'Est pour présenter ses résultats du troisième trimestre 2024. Le webcast audio sera accessible via le site web de l'entreprise et restera disponible pour rediffusion pendant 90 jours après l'événement.
Cassava Sciences (Nasdaq: SAVA), ein klinisches Biotech-Unternehmen, das sich auf Alzheimer konzentriert, hat angekündigt, dass es am Donnerstag, den 7. November 2024, um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten wird, um die Ergebnisse des dritten Quartals 2024 zu präsentieren. Der Audio-Webcast wird über die Unternehmens-Website zugänglich sein und bleibt 90 Tage nach der Veranstaltung für eine Wiederholung verfügbar.
- None.
- None.
Conference call and webcast to begin at 8:30 AM ET
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.
| Event details: | |
| Date: | Thursday, November 7th |
| Time: | 8:30 a.m. Eastern Time |
| Audio Webcast: | https://www.CassavaSciences.com/company-presentations |
| Or | |
| Audio Webcast: | https://edge.media-server.com/mmc/p/tzb9j3sy |
A replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.
Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Investors
Sandya van der Weid
svonderweid@lifesciadvisors.com
Media
Sitrick And Company
Mike_Sitrick@Sitrick.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
FAQ
When will Cassava Sciences (SAVA) report Q3 2024 earnings?
How can I access Cassava Sciences (SAVA) Q3 2024 earnings call?
How long will Cassava Sciences (SAVA) Q3 2024 earnings call replay be available?
